STIMOLA CURIOSITA’, PASSIONE E CORAGGIO
Proteoglycan-4 as coadjuvant treatment to overcome resistance to sorafenib and Regorafenib in patients with Hepatocellular carcinoma
Proof Of Concept (POC) - PNRR M6/C2 2023
Abstract
Sorafenib and regorafenib are the drugs most commonly used in patients with hepatocellular carcinoma (HCC), providing a disease control rate of approximately 40% of cases. Nevertheless, 30% of patients develop resistance to treatment.
Recently, we have demonstrated that an extracellular matrix component, named Proteoglycan-4 (PRG4), physiologically present in the body, works as a novel tumor-suppressive agent by strengthening sorafenib and regorafenib effects in "in vitro" models of HCC. Based on this finding, we have deposited a patent for the development of PRG4 as an adjuvant agent to overcome resistance to Sorafenib and Regorafenib. This project aims to develop the scientific prototype as follows: 1) to investigate the effectiveness of PRG4 in combination with Sorafenib and Regorafenib in in vivo models; 2) to investigate the effectiveness of PRG4 on immune cells infiltrating HCC; 3) to individuate the shorter aminoacidic sequence mimicking the PRG4 adjuvant effectiveness.
Partenariato
- Ente Ospedaliero specializzato in gastroenterologia Saverio De Bellis
- IRCCS Humanitas Research Hospital
- Biogem scarl
- Università degli Studi di Udine
Importo del progetto
Importo totale del progetto Euro 1.183.000,00
Importo del progetto Uniud Euro 246.000,00
Finanziamento Uniud Euro 0,00
Durata
- Dal 31.08.2024
- Al 30.08.2026
Link